Features of the course and outcomes of pregnancy in primiparous women with early preeclampsia
DOI:
https://doi.org/10.15574/HW.2025.5(180).4753Keywords:
pregnancy, primiparous women, maternal age, pregnancy course, labor and delivery, neonatal status, pregnancy and labor complications, early preeclampsia, fetal growth retardation, risk factorsAbstract
Aim - to study the features of the course and outcomes of pregnancy in primiparous women with early preeclampsia to predict and optimize obstetric tactics in them.
Materials and methods. An analysis of pregnancy outcomes was conducted in 78 primiparous women. Participants were divided into two groups: Group I - 38 pregnant women with early preeclampsia, Group II - 40 pregnant women without early preeclampsia. The study evaluated the incidence of pregnancy complications, levels of human beta-chorionic gonadotropin (beta-hCG) and pregnancy-associated plasma protein-A (PAPP-A), as well as Doppler parameters of the uterine arteries at 18-21 weeks of gestation. Statistical processing was performed using standard software.
Results. The course of pregnancy in primiparous women with early preeclampsia was characterized by a significant 1.6-fold increase in the incidence of gestational anemia: 14 (36.8%) cases in Group I versus 9 (22.5%) in Group II. Early placental insufficiency (PI) with fetal growth retardation syndrome (GRS) was also significantly more frequent in Group I - 18 (47.4%) cases compared to 3 (7.5%) in Group II. Pregnancy outcomes in these women included the birth of children with significantly lower body weight (2288.8±620.4 g) and body length (49.2±4.4 cm); an Apgar score of <7 points was recorded in 23.6% of cases.
Conclusions. Key features of pregnancy in primiparous women with early preeclampsia include PAPP-A levels below 2 ng/ml, hemodynamic disturbances in the fetoplacental complex at 18-21 weeks, and a high prevalence of gestational anemia (36.8%), early placental insufficiency with fetal growth retardation (47.4%), and oligohydramnios (15.8%).
The research was carried out in accordance with the principles of the Declaration of Helsinki. The study protocol was approved by the Local Ethics Committee of the institution mentioned in the paper. Informed consent was obtained from all participants prior to the study.
The author declares no conflict of interest.
References
American College of Obstetricians and Gynecologists. (2020). Gestational hypertension and preeclampsia: ACOG practice bulletin, number 222. Obstetrics & Gynecology. 135(6): e237-e260. https://doi.org/10.1097/AOG.0000000000003891; PMid:32443079 PMCid:PMC8907436
Ananth CV, Brandt JS. (2021). Incidence of early-onset preeclampsia: Population-based estimates. Hypertension. 77(4): 1234-1242.
Bartsch E, Medcalf KE, Park AL, Ray JG. (2020). Clinical risk factors for pre-eclampsia determined in early pregnancy: Systematic review and meta-analysis of large cohort studies. BMJ. 368: m675.
Brosens I, Pijnenborg R, Vercruysse L, Romero R. (2021). The "Great Obstetrical Syndromes" revisited: Emerging concepts in placental pathology. American Journal of Obstetrics and Gynecology. 224(2): S1-S10.
Burton GJ, Redman CW, Roberts JM, Moffett A. (2019). Pre-eclampsia: Pathophysiology and clinical implications. BMJ. 366: l2381. https://doi.org/10.1136/bmj.l2381; PMid:31307997 PMCid:PMC12042644
Dimitriadis E, Rolnik DL, Zhou W et al. (2023). Pre-eclampsia: Molecular mechanisms and clinical outcomes. Nature Reviews Nephrology. 19(4): 223-238.
Duley L. (2009). The global impact of pre-eclampsia and eclampsia. Seminars in Perinatology. 33(3): 130-137. https://doi.org/10.1053/j.semperi.2009.02.010; PMid:19464502 PMCid:PMC12042644
Hernandez-Diaz S, Toh S, Cnattingius S. (2022). Risk of pre-eclampsia in first and subsequent pregnancies: Prospective cohort study. BMJ. 378: e070823.
Hod T, Cerdeira AS, Karumanchi SA. (2023). Molecular mechanisms of preeclampsia: Current insights and future directions. Annual Review of Medicine. 74: 297-312.
Magee LA, Nicolaides KH, von Dadelszen P. (2022). Preeclampsia: Advances in management and prediction. New England Journal of Medicine. 386(19): 1817-1832. https://doi.org/10.1056/NEJMra2109523; PMid:35544388
Mintser OP. (2010). Statystychni metody v klinichnykh doslidzhenniakh. Kyiv: Vydavnychyi dim «Medytsyna».
O'Gorman N, Wright D, Poon LC et al. (2020). Multicenter screening for pre-eclampsia by maternal factors and biomarkers at 11-13 weeks' gestation. Ultrasound in Obstetrics & Gynecology. 56(2): 186-195.
Poon LC, Shennan A, Hyett JA et al. (2019). The International Federation of Gynecology and Obstetrics (FIGO) initiative on pre-eclampsia: A pragmatic guide for first-trimester screening and prevention. International Journal of Gynecology & Obstetrics. 145; Suppl 1: 1-33. https://doi.org/10.1002/ijgo.12802; PMid:31111484 PMCid:PMC6944283
Rana S, Lemoine E, Granger JP, Karumanchi SA. (2022). Preeclampsia: Pathophysiology, challenges, and perspectives. Circulation Research. 130(7): 1094-1112. https://doi.org/10.1161/CIRCRESAHA.118.313276; PMid:30920918 PMCid:PMC12042644
Robillard PY, Dekker G, Hulsey TC. (2020). Revisiting the epidemiological standard of preeclampsia: Primigravidity versus primipaternity. European Journal of Obstetrics & Gynecology and Reproductive Biology. 253: 226-232.
Rolnik DL, Wright D, Poon LC et al. (2020). Aspirin versus placebo in pregnancies at high risk for preterm preeclampsia. New England Journal of Medicine. 382(7): 613-622. https://doi.org/10.1056/NEJMoa1704559; PMid:28657417
Romero R. (1996). The great obstetrical syndromes. American Journal of Obstetrics and Gynecology. 175(4): 1043-1044.
Romero R, Chaiworapongsa T. (2022). Preeclampsia: A syndrome with multiple etiologies and phenotypes. American Journal of Obstetrics and Gynecology. 226(2S): S1039-S1050.
Say L, Chou D, Gemmill A et al. (2023). Global causes of maternal death: A WHO systematic analysis. The Lancet Global Health. 11(1): e22-e33.
Skjaerven R, Wilcox AJ, Lie RT. (2023). The interval between pregnancies and the risk of preeclampsia. Obstetrics & Gynecology. 141(1): 123-130.
Staff AC. (2020). The two-stage placental model of preeclampsia: An update. Journal of Reproductive Immunology. 141: 103174.
Steegers-Theunissen RPM, Steegers EAP. (2021). Challenges in diagnosing and managing preeclampsia. The Lancet. 398(10308): 1332-1343.
Tan MY, Wright D, Syngelaki A et al. (2021). Comparison of diagnostic accuracy of early screening for pre-eclampsia by NICE guidelines and a method combining maternal factors and biomarkers. Ultrasound in Obstetrics & Gynecology. 57(3): 418-426.
Townsend R, Khalil A, Thilaganathan B. (2021). Risk factors and predictive models for preeclampsia. Best Practice & Research Clinical Obstetrics & Gynaecology. 75: 66-77.
World Health Organization. (2024). Trends in maternal mortality 2000 to 2020: Estimates by WHO, UNICEF, UNFPA, World Bank Group and the United Nations Population Division. Geneva: WHO.
Wu P, Haththotuwa R, Kwok CS et al. (2021). Preeclampsia and future cardiovascular risk among women: A review. Journal of the American College of Cardiology. 77(14): 1814-1826.
Downloads
Published
Issue
Section
License
Copyright (c) 2025 Ukrainian Journal Health of Woman
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.
The policy of the Journal UKRAINIAN JOURNAL «HEALTH OF WOMAN» is compatible with the vast majority of funders' of open access and self-archiving policies. The journal provides immediate open access route being convinced that everyone – not only scientists - can benefit from research results, and publishes articles exclusively under open access distribution, with a Creative Commons Attribution-Noncommercial 4.0 international license (СС BY-NC).
Authors transfer the copyright to the Journal UKRAINIAN JOURNAL «HEALTH OF WOMAN» when the manuscript is accepted for publication. Authors declare that this manuscript has not been published nor is under simultaneous consideration for publication elsewhere. After publication, the articles become freely available on-line to the public.
Readers have the right to use, distribute, and reproduce articles in any medium, provided the articles and the journal are properly cited.
The use of published materials for commercial purposes is strongly prohibited.
